Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

China's biotech sector is on a tear. The Hang Seng Biotech Index has climbed over 60% since Januaryhandily beating China tech ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer’s deal announced two weeks earlier.

US drugmakers are betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

In a resounding vote of confidence in China's biotechnology sector, leading global pharmaceutical companies are striking multibillion-dollar deals for innovative therapies developed by Chinese firms.

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD ...

The rally in the sector this year outpaces the 17% gain in China’s tech stocks that was driven by the release of DeepSeek’s ...